Dose the first patient at a first visit in the NATIV3 Phase III trial
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 4 Mar 2021
- Due
- 30 Sep 2021
- Delivered
- November 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“First Patient First Visit – expected in the third quarter of 2021”
What we found
Evidence strength A What the grades mean
Filings show the trial was initiated and patients were screened by September 8, 2021, but the first patient was enrolled in November 2021, after the Q3 2021 deadline.
-
A Inventiva S.A. 20-F filed 2022-03-11
“the enrolment of the first patient took place in November 2021” ✓ confirmed on the page
-
A Inventiva S.A. 20-F filed 2022-03-11
“The first clinical trial sites have been activated in the United States and first patients have been screened.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- First patient first visit in NATIV3 Phase III trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Inventiva S.A.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IVA-025122 · Corrections policy